For proof-of-concept assays, the initial selection was limited to five clinically used anti-TB drugs: the first-line agents, INH and ethambutol (EMB), which disrupt cell-wall biosynthesis (Abrahams and Besra, 2018); RIF, which binds the DNA-dependent RNA polymerase subunit, RpoB (Koch et al., 2014); the second-line fluoroquinolone, moxifloxacin (MOXI), which inhibits DNA gyrase (Kumar et al., 2014) and bedaquiline (BDQ), an inhibitor of mycobacterial ATP biosynthesis recently approved for the treatment of MDR-TB (Sarathy et al., 2019). Here, TOP2A is linked to tuberculosis.